Sudeep Pharma
NSE: SUDEEPPHRM · Pharmaceuticals
Snapshot
Unlock Sudeep Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sudeep Pharma Limited is a manufacturer and supplier of excipients, mineral salts, and specialty ingredients for the pharmaceutical, food, and nutrition sectors. The company provides a diverse range of mineral-based solutions, including calcium, zinc, and iron, alongside micronutrient premixes and encapsulated ingredients.
Business Model
The company generates revenue through the manufacturing, processing, and global distribution of pharmaceutical excipients, nutraceutical ingredients, and food additives. It operates across the entire value chain, including the import, export, marketing, and testing of chemical and healthcare products.
- Incorporation Year:1989
Growth Outlook
Growth is driven by the increasing demand for functional foods, dietary supplements, and infant nutrition products globally. The company continues to expand its portfolio of specialized formats, such as liposomal and spray-dried ingredients, to cater to evolving healthcare and consumer goods requirements.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight in international markets, requiring continuous adherence to global pharmaceutical and food safety standards.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials, such as mineral salts and chemical precursors, may impact profit margins.
- Currency Risk. As an exporter to the United States, Europe, and the United Kingdom, the company is exposed to foreign exchange rate volatility.
- Competitive Pressure. The specialty ingredients market is highly competitive, necessitating constant innovation and investment in manufacturing capabilities to maintain market share.
Start your research today
Unlock AI insights, financials, peers and live data on Sudeep Pharma and 5,000+ companies — free.
Key Metrics
P/E
65.7×
Q2 FY27 · consolidated
EV/EBITDA
45.9x
Q2 FY27 · consolidated
NET PROFIT MARGIN
26.3%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sudeep PharmaSUDEEPPHRM | ₹12,506 Cr | 65.7× | 45.90 | — | 38.8% | 22.4% | 27.7% | — |
Jubilant Pharmova Ltd.JUBLPHARMA | ₹15,080 Cr | 42.6× | 13.18 | 16.3% | 15.0% | 5.3% | 6.5% | -14.0% |
Marksans Pharma LimitedMARKSANS | ₹14,156 Cr | 27.4× | 16.61 | 57.4% | 25.7% | 31.9% | 39.6% | +71.5% |
Corona RemediesCORONA | ₹13,278 Cr | 64.1× | 38.62 | — | 22.2% | 28.3% | 33.9% | — |
Concord Biotech Ltd.CONCORDBIO | ₹12,172 Cr | 43.6× | 26.88 | 4.0% | 38.7% | 14.3% | 18.8% | -19.4% |
Akums Drugs and Pharmaceuticals Ltd.AKUMS | ₹11,539 Cr | 38.5× | 16.04 | 9.2% | 15.6% | 9.2% | 13.8% | +59.1% |
As of Q2 FY27
Financials
Sudeep Pharma
NSE: SUDEEPPHRM · Pharmaceuticals
Snapshot
Unlock Sudeep Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sudeep Pharma Limited is a manufacturer and supplier of excipients, mineral salts, and specialty ingredients for the pharmaceutical, food, and nutrition sectors. The company provides a diverse range of mineral-based solutions, including calcium, zinc, and iron, alongside micronutrient premixes and encapsulated ingredients.
Business Model
The company generates revenue through the manufacturing, processing, and global distribution of pharmaceutical excipients, nutraceutical ingredients, and food additives. It operates across the entire value chain, including the import, export, marketing, and testing of chemical and healthcare products.
- Incorporation Year:1989
Growth Outlook
Growth is driven by the increasing demand for functional foods, dietary supplements, and infant nutrition products globally. The company continues to expand its portfolio of specialized formats, such as liposomal and spray-dried ingredients, to cater to evolving healthcare and consumer goods requirements.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight in international markets, requiring continuous adherence to global pharmaceutical and food safety standards.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials, such as mineral salts and chemical precursors, may impact profit margins.
- Currency Risk. As an exporter to the United States, Europe, and the United Kingdom, the company is exposed to foreign exchange rate volatility.
- Competitive Pressure. The specialty ingredients market is highly competitive, necessitating constant innovation and investment in manufacturing capabilities to maintain market share.
Start your research today
Unlock AI insights, financials, peers and live data on Sudeep Pharma and 5,000+ companies — free.
Key Metrics
P/E
65.7x
Q2 FY27 · consolidated
EV/EBITDA
45.9x
Q2 FY27 · consolidated
NET PROFIT MARGIN
26.3%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
As of Q2 FY27